Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome

被引：0
|
作者：
Kibum Kim
Daniel R. Touchette
Larisa H. Cavallari
Amer K. Ardati
Robert J. DiDomenico
机构：
[1] University of Utah,Department of Pharmacotherapy and Pharmacotherapy Outcomes Research Center
[2] University of Illinois at Chicago,Center for Pharmacoepidemiology and Pharmacoeconomic Research
[3] University of Illinois at Chicago,Department of Pharmacy Systems, Outcomes and Policy
[4] University of Florida,Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics
[5] University of Illinois at Chicago,Division of Cardiology
[6] University of Illinois at Chicago,Department of Pharmacy Practice
来源：
Cardiovascular Drugs and Therapy | 2019年 / 33卷
关键词：
Acute coronary syndrome; Personalized medicine; Ticagrelor; Clopidogrel; P2Y; inhibitors; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：533 / 546
页数：13
相关论文
共 50 条
  • [1] Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome
    Kim, Kibum
    Touchette, Daniel R.
    Cavallari, Larisa H.
    Ardati, Amer K.
    DiDomenico, Robert J.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (05) : 533 - 546
  • [2] EXAMINING THE COST-EFFECTIVENESS OF EMPIRICAL PASSIVE PERSONALIZATION WITH P2Y12 INHIBITORS IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Suh, Kangho
    Basu, Anirban
    Branch, Kelley
    Carlson, Josh
    MEDICAL DECISION MAKING, 2020, 40 (01) : E74 - E75
  • [3] Comparison of Oral P2Y12 Inhibitors in Acute Coronary Syndrome
    Ferracane, Elisa
    Bartoli, Laura
    Trippoli, Sabrina
    Messori, Andrea
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 135 : 183 - 184
  • [4] Choice of P2Y12 Inhibitors After Acute Coronary Syndrome
    Ando, Giuseppe
    Gragnano, Felice
    Pelliccia, Francesco
    Calabro, Paolo
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 211 : 377 - 377
  • [5] Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
    Christodoulidis, Georgios
    Baber, Usman
    Mehran, Roxana
    CURRENT OPINION IN CARDIOLOGY, 2014, 29 (04) : 301 - 306
  • [6] Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
    Tantry, Udaya S.
    Navarese, Eliano P.
    Myat, Aung
    Gurbel, Paul A.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2018, 60 (4-5) : 460 - 470
  • [7] Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients Cost-effectiveness analyses for six European perspectives
    Coleman, Craig I.
    Limone, Brendan L.
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (01) : 103 - 110
  • [8] Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes
    Dong, Olivia M.
    Friede, Kevin A.
    Chanfreau-Coffinier, Catherine
    Voora, Deepak
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2023, 9 (03) : 249 - 257
  • [9] Efficacy and safety of newer P2Y12 inhibitors versus clopidogrel in patients with acute coronary syndrome
    Fei, Y.
    Lam, C.
    Cheung, B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1631 - 1631
  • [10] Patterns of use of P2Y12 inhibitors in patients with acute coronary syndrome in routine clinical practice
    Yuan, Zhong
    Hardin, Jill
    Voss, Erica A.
    Hester, Laura L.
    Weaver, James
    Davis, Kourtney
    Barnathan, Elliot S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 143 - 143
12345